Conventional drug therapy for inflammatory bowel disease

被引：70

作者：

Bryant, Robert V. ^{[1
]}

Brain, Oliver ^{[1
]}

Travis, Simon P. L. ^{[1
]}

机构：

[1] Oxford Univ Hosp Trust, Translat Gastroenterol Unit, Oxford OX3 9DU, England

来源：

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | 2015年 / 50卷 / 01期

关键词：

Crohn's disease; inflammatory bowel disease; ulcerative colitis; ACTIVE ULCERATIVE-COLITIS; EVIDENCE-BASED CONSENSUS; RELEASE ORAL MESALAMINE; EARLY COMBINED IMMUNOSUPPRESSION; INFLIXIMAB MAINTENANCE THERAPY; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; QUALITY-OF-LIFE; CROHNS-DISEASE;

D O I：

10.3109/00365521.2014.968864

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Most patients with inflammatory bowel diseases (IBD) are offered conventional medical therapy, because emerging therapies for IBD are regulated by health-care jurisdiction and often limited to academic centres. This review distils current evidence to provide a pragmatic approach to conventional IBD therapy, including aminosalicylates, corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, infliximab and adalimumab. It addresses drug efficacy, safety and salient practice points for optimal and appropriate practice.

引用

页码：90 / 112

页数：23

共 209 条

[1]

Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients [J].

Aberra, FN ;

Lewis, JD ;

Hass, D ;

Rombeau, JL ;

Osborne, B ;

Lichtenstein, GR .

GASTROENTEROLOGY, 2003, 125 (02) :320-327

[2]

Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study [J].

Actis, Giovanni C. ;

Fadda, Maurizio ;

David, Ezio ;

Sapino, Anna .

BMC GASTROENTEROLOGY, 2007, 7 (1)

[3]

Moving towards disease modification in inflammatory bowel disease therapy [J].

Allen, Patrick B. ;

Peyrin-Biroulet, Laurent .

CURRENT OPINION IN GASTROENTEROLOGY, 2013, 29 (04) :397-404

[4]

Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases [J].

Ananthakrishnan, Ashwin N. ;

Nguyen, Deanna D. ;

Sauk, Jenny ;

Yajnik, Vijay ;

Xavier, Ramnik J. .

INFLAMMATORY BOWEL DISEASES, 2014, 20 (05) :783-789

[5]

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].

Ardizzone, S ;

Maconi, G ;

Russo, A ;

Imbesi, V ;

Colombo, E ;

Porro, GB .

GUT, 2006, 55 (01) :47-53

[6]

Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis [J].

Arts, J ;

D'Haens, G ;

Zeegers, M ;

Van Assche, G ;

Hiele, M ;

D'Hoore, A ;

Penninckx, F ;

Vermeire, S ;

Rutgeerts, P .

INFLAMMATORY BOWEL DISEASES, 2004, 10 (02) :73-78

[7]

Risk Factors for Osteoporosis in Crohn's Disease: Infliximab, Corticosteroids, Body Mass Index, and Age of Onset [J].

Azzopardi, Neville ;

Ellul, Pierre .

INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) :1173-1178

[8]

Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation [J].

Bakker, Sjoerd F. ;

Dik, Vincent K. ;

Witte, Birgit I. ;

Lips, Paul ;

Roos, Jan C. ;

Van Bodegraven, Adriaan A. .

JOURNAL OF CROHNS & COLITIS, 2013, 7 (05) :377-384

[9]

BARON J H, 1962, Br Med J, V2, P441

[10]

Predictors of Crohn's disease [J].

Beaugerie, L ;

Seksik, P ;

Nion-Larmurier, I ;

Gendre, JP ;

Cosnes, J .

GASTROENTEROLOGY, 2006, 130 (03) :650-656

← 1 2 3 4 5 6 7 8 9 10 →